Giant Eagle Pharmacy #4035 Community/Retail Pharmacy Location: 606 Erie St, Edinboro, Pennsylvania 16412 Phone: (814) 734-5036 |
Cvs Pharmacy #05095 Durable Medical Equipment & Medical Supplies Location: 124 Erie St, Edinboro, Pennsylvania 16412 Phone: (814) 734-5207 |
Wal-mart Pharmacy 10-3253 Durable Medical Equipment & Medical Supplies Location: 108 Washington Towne Blvd N, Edinboro, Pennsylvania 16412 Phone: (814) 734-3770 |
News Archive
Urovalve, a medical device company focused on creating superior products for urinary flow and control, reported today that early results are promising in a multi-site clinical study of the Company's Surinate® Bladder Management System. The Surinate® Bladder Management System is designed to improve the quality of life and health of men who suffer from acute or chronic urinary retention, an inability to empty the bladder.
Attagene Inc., a leader in developing innovative technologies for analyzing gene regulatory pathways, announced today the online publication of a paper in Chemical Research in Toxicology, a journal of the American Chemical Society, that highlights results of their collaborative work with the Environmental Protection Agency's National Center for Computational Toxicology (NCCT).
Professor Vivien Chen, PhD,. Associate Professor Xiao Cheng Wu, MD, PhD and Assistant Professor Edward Peters, DMD, SM, ScD, at LSU Health Sciences Center New Orleans School of Public Health contributed five papers to the largest most comprehensive assessment of the burden of human papillomavirus (HPV)-associated cancers in the United States to date.
University of Texas Medical Branch at Galveston researchers have been awarded a five-year, $1.8 million grant by the National Institute of Neurological Disorders and Stroke to apply the techniques of gene therapy to the problem of neuropathic pain - that is, pain that arises from a malfunction in the nervous system.
QLT Inc. today announced that, subject to regulatory approval, the Board of Directors has approved an increase in the number of common shares that QLT may purchase under its normal course issuer bid over the twelve month period that commenced on November 3, 2009, from 2,731,534 common shares, representing 5% of the outstanding common shares on October 28, 2009, to 4,700,060 common shares, representing 10% of the public float as at that date.
› Verified 6 days ago